Atlas Trials

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Clinical trial NCT04848337 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04848337
Sponsor
University of Michigan Rogel Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer MetastaticNeuroendocrine Tumors
Start date
2021-05-25
Primary completion
2025-01-08
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.